Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF) Shares Shorted: Short Interest Down 98.4% in September

Shanghai Junshi Biosciences Co., Ltd. (OTCMKTS:SHJBF – Get Free Report) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totaling 1,000 shares, a drop of 98.4% from the August 31st total of 63,000 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ? days.

Shanghai Junshi Biosciences Price Performance

Shanghai Junshi Biosciences stock remained flat at C$3.35 during mid-day trading on Friday. Shanghai Junshi Biosciences has a 1-year low of C$2.99 and a 1-year high of C$4.23. The company’s 50 day moving average is C$3.35 and its two-hundred day moving average is C$3.24.

Shanghai Junshi Biosciences Company Profile

(Get Free Report)

Shanghai Junshi Biosciences Co, Ltd. is a Shanghai-based biopharmaceutical company dedicated to the research, development and commercialization of monoclonal antibody therapeutics. Since its founding in 2012 as a spin-off from the Shanghai Institute of Pharmaceutical Industry, Junshi has focused on leveraging cutting-edge antibody engineering platforms to develop innovative treatments for oncology, autoimmune conditions, infectious diseases and metabolic disorders. The company’s lead product, toripalimab (Tuoyi), was among the first anti-PD-1 antibodies approved by Chinese regulatory authorities for the treatment of advanced melanoma and nasopharyngeal carcinoma, demonstrating Junshi’s capability to translate research into commercially available immuno-oncology therapies.

Junshi’s pipeline encompasses a diversified portfolio of antibody-based candidates targeting immune checkpoints, cytokines and other disease-associated proteins.

Featured Stories

Receive News & Ratings for Shanghai Junshi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shanghai Junshi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.